Перспективы применения упадацитиниба при ревматоидном артрите и других иммуновоспалительных ревматических заболеваниях
Аннотация
Расшифровка механизмов патогенеза ревматоидного артрита в сочетании с разработкой широкого спектра генно-инженерных биологических препаратов относятся к числу крупных достижений медицины XXI в. Новое направление фармакотерапии иммуновоспалительных ревматических заболеваний связано с созданием «таргетных» пероральных лекарственных противовоспалительных препаратов, к которым относятся ингибиторы янус-киназ. Представителем класса этих ингибиторов является упадацитиниб, который зарегистрирован для лечения ревматоидного артрита и проходит клинические испытания при анкилозирующем спондилите, псориатическом артрите и других иммуновоспалительных ревматических заболеваниях. В обзоре представлены новые данные, касающиеся эффективности и безопасности упадацитиниба при ревматоидном артрите.
Об авторах
Е. Л. Насонов
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)
Россия
Россия
Насонов Евгений Львович — д.м.н., профессор, академик РАН, научный руководитель ФГБНУ «НИИР им. В.А. Насоновой»
115522, Москва, Каширское шоссе, 34а
119991, Москва, ул. Трубецкая, 8, стр. 2
А. М. Лила
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской Федерации
Россия
Россия
Лила А.М. — д.м.н., профессор, директор ФГБНУ «НИИР им. В.А. Насоновой»
115522, Москва, Каширское шоссе, 34а
125993, Москва, ул. Баррикадная, 2/1, стр. 1
Список литературы
1. Baker K.F., Isaacs J.D. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175–187. DOI: 10.1136/annrheumdis-2017-211555
2. Насонов Е.Л. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409–419. [Nasonov E.L. Pharmacotherapy for rheumatoid arthritis: New strategy, new targets. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2017;55(4):409–419 (In Russ.)]. DOI: 10.14412/1995-4484-2017-409-419
3. Schwartz D.M., Kanno Y., Villarino A., et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843–862. DOI: 10.1038/nrd.2017.201
4. Насонов Е.Л., Лила А.М. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8–16. DOI: 10.14412/1995-4484-2019-8-16
5. Насонов Е.Л., Авдеева А.С., Лила А.М. Эффективность и безопасность тофацитиниба при иммуновоспалительных ревматических заболеваниях (часть I). Научно-практическая ревматология. 2020;58(1):62–79. DOI: 10.14412/1995-4484-2020-62-79
6. Dhillon S. Tofacitinib: A Review in Rheumatoid Arthritis. Drugs. 2017;77(18):1987–2001. DOI: 10.1007/s40265-017-0835-9
7. Насонов Е.Л., Лила А.М. Барицитиниб: новые возможности фармакотерапии ревматоидного артрита и других иммуновоспалительных ревматических заболеваний. Научнопрактическая ревматология. 2020;58(3):304–316. DOI: 10.14412/1995-4484-2020-304-316
8. Al-Salama Z.T., Scott L.J. Baricitinib: A review in rheumatoid arthritis. Drugs. 2018;78(7):761–772. DOI: 10.1007/s40265-018-0908-4
9. Serhal L., Edwards C.J. Upadacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2019;15(1):13–25. DOI: 10.1080/1744666X.2019.1544892
10. Tanaka Y. A review of upadacitinib in rheumatoid arthritis [published online ahead of print, 2020]. Mod Rheumatol. 2020;1–9. DOI: 10.1080/14397595.2020.1782049
11. Villarino A.V., Kanno Y., O’Shea J.J. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–384. DOI: 10.1038/ni.3691
12. Hosseini A., Gharibi T., Marofi F., Javadian M., Babaloo Z., Baradaran B. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases. J Cell Physiol. 2020;235(9):5903–5924. DOI: 10.1002/jcp.29593
13. Parmentier J.M., Voss J., Graff C., et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23. DOI: 10.1186/s41927-018-0031-x
14. McInnes I.B., Byers N.L., Higgs R.E., et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183. DOI: 10.1186/s13075-019-1964-1
15. Choy E.H. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford). 2019;58(6):953–962. DOI: 10.1093/rheumatology/key339. Erratum in: Rheumatology (Oxford). 2019 Jun 1;58(6):1122.
16. Dowty M.E., Lin T.H., Jesson M.I., et al. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacol Res Perspect. 2019;7(6):e00537. DOI: 10.1002/prp2.537
17. Mohamed M.F., Camp H.S., Jiang P., Padley R.J., Asatryan A., Othman A.A. Pharmacokinetics, safety and tolerability of ABT494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis. Clin Pharmacokinet. 2016;55(12):1547–1558. DOI: 10.1007/s40262-016-0419-y
18. Veeravalli V., Dash R.P., Thomas J.A., et al. Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment. Drug Saf. 2020;43(8):711–725. DOI: 10.1007/s40264-020-00938-z
19. Kremer J.M., Emery P., Camp H.S., et al. A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy. Arthritis Rheumatol. 2016;68(12):28672877. DOI: 10.1002/art.39801
20. Genovese M.C., Smolen J.S., Weinblatt M.E., et al. Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Arthritis Rheumatol. 2016;68(12):2857–2866. DOI: 10.1002/art.39808
21. Burmester G.R., Kremer J.M., Van den Bosch F., et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, doubleblind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503–2512. DOI: 10.1016/S0140-6736(18)31115-2
22. Genovese M.C., Fleischmann R., Combe B., et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513–2524. DOI: 10.1016/S0140-6736(18)31116-4
23. van Vollenhoven R., Takeuchi T., Pangan A.L., et al. Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-naïve Patients with Moderately to Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Randomized, Double-blind, Activecomparator, Multi-center, Multi-country Trial. Arthritis Rheumatol. 2020;10.1002/art.41384. DOI: 10.1002/art.41384
24. Fleischmann R., Pangan A.L., Song I.H., et al. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis Rheumatol. 2019;71(11):1788–1800. DOI: 10.1002/art.41032
25. Smolen J.S., Pangan A.L., Emery P., et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECTMONOTHERAPY): a randomised, placebo-controlled, doubleblind phase 3 study [published correction appears in Lancet. 2019 Jun 29;393(10191):2590]. Lancet. 2019;393(10188):2303–2311. DOI:10.1016/S0140-6736(19)30419-2
26. Rubbert-Roth A., Enejosa J., Pangan A.L., Haraoui B., Rischmueller M., Khan N., Zhang Y., Martin N., Xavier R.M. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. N Engl J Med. 2020;383(16):1511–1521. DOI: 10.1056/NEJMoa2008250
27. Kameda H., Takeuchi T.., Yamaoka K., Oribe M., Kawano M., Zhou Y., Othman A.A., Pangan A.L., Kitamura S., Meerwein S., Tanaka Y. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebocontrolled phase IIb/III study. Rheumatology (Oxford). 2020;59(11):3303–3313. DOI: 10.1093/rheumatology/keaa084.
28. Fleischmann R.M., Genovese M.C., Enejosa J.V., et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019;78(11):1454–1462. DOI: 10.1136/annrheumdis-2019-215764
29. Strand V., Pope J., Tundia N., et al. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic diseasemodifying antirheumatic drugs: results from SELECT-NEXT [published correction appears in Arthritis Res Ther. 2020 Jun 9;22(1):137]. Arthritis Res Ther. 2019;21(1):272. DOI: 10.1186/s13075-019-2037-1
30. Strand V., Schiff M., Tundia N., et al. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. Arthritis Res Ther. 2019;21(1):263. DOI: 10.1186/s13075-019-2059-8
31. Fleischmann R., Song I.H., Enejosa J., et al. [THU0201]. Longterm safety and effectiveness of upadacitinib or adalimumab in patients with rheumatoid arthritis: results at 72 weeks from the SELECT-COMPARE study. Ann Rheum Dis 2020;79:323. DOI: 10.1136/annrheumdis-2020-eular.1418
32. Smolen J.S., Emery P., Rigby W., et al. [THU0213]. Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 84 weeks from the SELECT-MONOTHERAPY study. Ann Rheum Dis. 2020;79:331–332. DOI: 10.1136/annrheumdis-2020-eular.961
33. Van Vollenhoven R., Takeuchi T., Rischmueller M., et al. [THU0217]. Upadacitinib monotherapy in methotrexate-naïve patients with rheumatoid arthritis: results at 72 weeks from SELECT-EARLY. Ann Rheum Dis. 2020;79:334–335. DOI: 10.1136/annrheumdis-2020-eular.1857
34. Van Vollenhoven R., Ostor A., Mysler E., et al. [FRI0138]. The impact of upadacitinib versus methotrexate or adalimumab on individual and composite disease measures in patients with rheumatoid arthritis. Ann Rheum Dis. 2020;79:651–652. DOI: 10.1136/annrheumdis-2020-eular.1426
35. Kapetanovic M.C., Andersson M., Friedman A., et al. [SAT0145]. Efficacy and safety of upadacitinib monotherapy in mtx-naïve patients with early active ra receiving treatment within 3 months of diagnosis: a post-hoc analysis of the SELECT-EARLY. Ann Rheum Dis. 2020;79:1011. DOI: 10.1136/annrheumdis-2020-eular.1431
36. Buch M., Wells A., Rubbert-Roth A., et al. Comparative Analysis of Upadacitinib Monotherapy and Upadacitinib Combination Therapy for the Treatment of Rheumatoid Arthritis from Two Phase 3 Trials [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/a-comparative-analysis-ofupadacitinib-monotherapy-and-upadacitinib-combination-therapyfor-the-treatment-of-rheumatoid-arthritis-from-two-phase-3trials/. Accessed August 20, 2020.
37. Genovese M.C., Fleischmann R., Blanco R., et al. [OP0029]. Switching between the jak1-selective inhibitor-upadacitinib and adalimumab following initial non-response: clinical and functional outcomes among rheumatoid arthritis patients. Ann Rheum Dis. 2019;78:83–84.
38. Peterfy C., Strand V., Genovese M.C., et al. [THU0211]. Radiographic outcomes in patients with rheumatoid arthritis receiving upadacitinib as monotherapy or in combination with methotrexate: results at 2 years from the SELECT-COMPARE and SELECT-EARLY studies. Ann Rheum Dis. 2020;79:330–331. DOI: 10.1136/annrheumdis-2020-eular.1869
39. Weinblatt M., Mysler E., Ostor A., et al. [FRI0140]. Impact of baseline demographics and disease activity on outcomes in patients with rheumatoid arthritis receiving upadacitinib. Ann Rheum Dis. 2020;79:653–654. DOI: 10.1136/annrheumdis-2020-eular.907
40. Насонов Е.Л. Абатацепт при ревматоидном артрите: новая форма, новые механизмы, новые возможности. Научнопрактическая ревматология. 2015;53(5):522–541. DOI: 10.14412/1995-4484-2015-522-541
41. Schiff M., Weinblatt M.E., Valente R., et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73(1):86–94. DOI: 10.1136/annrheumdis-2013-203843
42. Gossec L., Dougados M., Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open. 2015;1(1):e000019. DOI: 10.1136/rmdopen-2014-000019
43. Cohen S.B., Van Vollenhoven R., Curtis J.R., et al. [THU0197]. Safety profile of upadacitinib up to 3 years of exposure in patients with rheumatoid arthritis. Ann Rheum Dis. 2020;79:319–320. DOI: 10.1136/annrheumdis-2020-eular.2396
44. Winthrop K., Calabrese L., Van den Bosch F., et al. [FRI0141]. Characterization of serious infections with upadacitinib in patients with rheumatoid arthritis. Ann Rheum Dis. 2020;79:654–655. DOI: 10.1136/annrheumdis-2020-eular.2761
45. Winthrop K., Nash P., Yamaoka K., et al. [THU0218]. Incidence and risk factors for herpes zoster in rheumatoid arthritis patients receiving upadacitinib. Ann Rheum Dis. 2020;79:335–336. DOI: 10.1136/annrheumdis-2020-eular.2744
46. Choy E., Mcinnes I., Cush J., et al. [THU0195]. Incidence and risk of venous thromboembolic events among patients with rheumatoid arthritis enrolled in the upadacitinib SELECT clinical trial program. Ann Rheum Dis. 2020;79:317–318. DOI: 10.1136/annrheumdis-2020-eular.2897
47. Sepriano A., Kerschbaumer A., Smolen J.S., et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2020;79(6):760–770. DOI: 10.1136/annrheumdis-2019-216653
48. Kerschbaumer A., Sepriano A., Smolen J.S., et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020;79(6):744–759. DOI: 10.1136/annrheumdis-2019-216656
49. Song G.G., Choi S.J., Lee Y.H. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials. Int J Rheum Dis. 2019;22(8):1563–1571. DOI: 10.1111/1756-185X.13616
50. Lee Y.H., Song G.G. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis [published online ahead of print, 2020 Feb 13]. Relative Wirksamkeit und Sicherheit von Tofacitinib, Baricitinib, Upadacitinib und Filgotinib im Vergleich zu Adalimumab bei Patienten mit aktiver rheumatoider Arthritis [published online ahead of print, 2020 Feb 13]. Z Rheumatol. 2020;10.1007/s00393020-00750-1. DOI: 10.1007/s00393-020-00750-1
51. Jegatheeswaran J., Turk M., Pope J.E. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review. Immunotherapy. 2019;11(8):737–754. DOI: 10.2217/imt-2018-0178
52. Wang F., Sun L., Wang S., et al. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Mayo Clin Proc. 2020;95(7):1404–1419. DOI: 10.1016/j.mayocp.2020.01.039
53. Ho Lee Y., Gyu Song G. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis. J Clin Pharm Ther. 2020;45(4):674–681. DOI: 10.1111/jcpt.13142
54. Song G.G., Lee Y.H. Comparative efficacy and safety of 15 and 30 mg upadacitinib administered to patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Z Rheumatol. 2020;79(1):103–111. DOI: 10.1007/s00393-019-0601-3
55. Bechman K., Subesinghe S., Norton S., et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(10):1755–1766. DOI: 10.1093/rheumatology/kez087
56. Pharmacoeconomic Review Report: Upadacitinib (Rinvoq): (AbbVie). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2020.
57. Pope J., Sawant R., Tundia N., et al. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis. Adv Ther. 2020;37(5):2356–2372. DOI: 10.1007/s12325-020-01303-3
58. Edwards C., Sawant R., Du E., et al. [THU0168]. A matchingadjusted indirect comparison (MAIC) of upadacitinib versus tofacitinib in csdmard-ir patients with moderate to severe rheumatoid arthritis (RA). Ann Rheum Dis. 2019;78:358. DOI: 10.1136/annrheumdis-2019-eular.7189
59. van der Heijde D., Strand V., Tanaka Y., et al. Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. Arthritis Rheumatol. 2019;71(6):878–891. DOI: 10.1002/art.40803
60. Strand V., Kremer J.M., Gruben D., Krishnaswami S., Zwillich S.H., Wallenstein G.V. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial. Arthritis Care Res (Hoboken). 2017;69(4):592–598. DOI: 10.1002/acr.23004
61. van Vollenhoven R.F., Fleischmann R., Cohen S., et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis [published correction appears in N Engl J Med. 2013 Jul 18;369(3):293]. N Engl J Med. 2012;367(6):508–519. DOI: 10.1056/NEJMoa1112072
62. Fleischmann R., Mysler E., Hall S., et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-tohead, randomised controlled trial. Lancet. 2017;390(10093):457–468. DOI: 10.1016/S0140-6736(17)31618-5
63. Dougados M., van der Heijde D., Chen Y.C., et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study [published correction appears in Ann Rheum Dis. 2017 Sep;76(9):1634]. Ann Rheum Dis. 2017;76(1):88–95. DOI: 10.1136/annrheumdis-2016-210094
64. Taylor P.C., Keystone E.C., van der Heijde D., et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017;376(7):652–662. DOI: 10.1056/NEJMoa1608345
65. Li Z., Hu J., Bao C., et al. [SAT0218]. Efficacy and safety of baricitinib in mtx-ir patients with rheumatoid arthritis: 52 week results from a phase 3 study (RA-BALANCE). Ann Rheum Dis. 2018;77:969–970. DOI: 10.1136/annrheumdis-2018-eular.1983
66. Bechman K., Subesinghe S., Norton S., et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(10):1755–1766. DOI: :10.1093/rheumatology/kez087
67. Smolen J.S., Landewé R.B.M., Bijlsma J.W.J., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699. DOI: 10.1136/annrheumdis-2019-216655
68. van der Heijde D., Song I.H., Pangan A.L., et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019; 394(10214):2108–2117. DOI: 10.1016/S0140-6736(19)32534-6
69. Kiltz U., Sieper J., Deodhar A., et al. [THU0375]. Improvements in global functioning and health-related quality of life and their association with disease activity and functional improvement in patients with active ankylosing spondylitis treated with upadacitinib: results from the select-axis 1 trial. Ann Rheum Diseases. 2020;79:420–421. DOI: 10.1136/annrheumdis-2020-eular.857
70. Mcinnes I., Anderson J., Magrey M., et al. [LB0001]. Efficacy and safety of upadacitinib versus placebo and adalimumab in patients with active psoriatic arthritis and inadequate response to nonbiologic disease-modifying anti-rheumatic drugs (SELECT-PsA-1): a double-blind, randomized controlled phase 3 trial. Ann Rheum Dis. 2020;79:16–17. DOI: 10.1136/annrheumdis-2020-eular.6727
71. Genovese M.C., Lertratanakul A., Anderson J., et al. [OP0223]. efficacy and safety of upadacitinib in patients with active psoriatic arthritis and inadequate response to biologic disease-modifying anti-rheumatic drugs (SELECT-PSA-2): a double-blind, randomized controlled phase 3 trial. Ann Rheum Dis. 2020;79:139. DOI: 10.1136/annrheumdis-2020-eular.1229
72. Насонов Е.Л. Метотрексат при ревматоидном артрите — 2015: новые факты и идеи. Научно-практическая ревматология. 2015;53(4):421–433. DOI: 10.14412/1995-4484-2015-421-433
73. Chatzidionysiou K., Sfikakis P.P. Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift. RMD Open. 2019;5(2):e000993. Published 2019 Jul 27. DOI: 10.1136/rmdopen-2019-000993
74. Doria A., Zavaglia D. Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review. Clin Exp Rheumatol. 2019;37(5):862–871.
75. Choy E., Aletaha D., Behrens F., et al. Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Rheumatology (Oxford). 2017;56(5):689–697. DOI: 10.1093/rheumatology/kew271
76. Насонов Е.Л., Олюнин Ю.А., Лила А.М. Ревматоидный артрит: проблемы ремиссии и резистентности к терапии. Научно-практическая ревматология. 2018;56(3):263–271. DOI: 10.14412/1995-4484-2018-263-271
77. Oray M., Abu Samra K., Ebrahimiadib N., et al. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457–465. DOI: 10.1517/14740338.2016.1140743
78. Gianfrancesco M., Hyrich K.L., Al-Adely S., et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859–866. DOI: 10.1136/annrheumdis-2020-217871
79. Takeuchi T., Genovese M.C., Haraoui B., et al. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Ann Rheum Dis. 2019;78(2):171–178. DOI: 10.1136/annrheumdis-2018-213271
80. Schwartz D.M., Bonelli M., Gadina M., O’Shea J.J. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25–36. DOI: 10.1038/nrrheum.2015.167
81. Firestein G.S., McInnes I.B. Immunopathogenesis of Rheumatoid Arthritis. Immunity. 2017;46(2):183–196. DOI: 10.1016/j.immuni.2017.02.006
82. Sornasse T., Sokolove J., McInnes I. Treatment with Upadacitinib Results in the Normalization of Key Pathobiologic Pathways in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/treatment-with-upadacitinib-results-in-the-normalization-ofkey-pathobiologic-pathways-in-patients-with-rheumatoidarthritis/. Accessed August 21, 2020.
83. Lent S., Sornasse T., Georgantas R., Sokolove J., McInnes I. Molecular Analysis of the Mode of Action of Upadacitinib in Rheumatoid Arthritis Patients: Whole Blood RNA Expression Data from the SELECT-NEXT Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/molecular-analysis-of-the-mode-of-action-of-upadacitinib-inrheumatoid-arthritis-patients-whole-blood-rna-expression-datafrom-the-select-next-study.
84. Sornasse T., Song I.H., Radstake T., et al. [FRI0026]. Proteomics analysis comparing the mode of action of upadacitinib and adalimumab head to head in ra identifies novel, discrete early immune pathway modulation in the SELECT-COMPARE phase 3 study. Ann Rheum Dis. 2020;79:585–586. DOI: 10.1136/annrheumdis-2020-eular.1908
Рецензия
Для цитирования:
Насонов Е.Л., Лила А.М. Перспективы применения упадацитиниба при ревматоидном артрите и других иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2020;58(5):532-543. https://doi.org/10.47360/1995-4484-2020-532-543
For citation:
Nasonov E.L., Lila A.M. The progress of rheumatology in the 21st century potential uses of upadacitinib in rheumatoid arthritis and other inflammatory rheumatic diseases. Rheumatology Science and Practice. 2020;58(5):532-543. https://doi.org/10.47360/1995-4484-2020-532-543
Просмотров: 610
Послать статью по эл. почте 
